NRC-2694 is under clinical development by Natco Pharma and currently in Phase II for Recurrent Head And Neck Cancer Squamous Cell Carcinoma. According to GlobalData, Phase II drugs for Recurrent Head And Neck Cancer Squamous Cell Carcinoma have a 37% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how NRC-2694’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

NRC-2694 overview

NRC-2694 is under development for the treatment of recurrent head and neck cancer squamous cell carcinoma, oral cavity (mouth) cancer, oropharyngeal cancer, hypopharyngeal cancer, laryngeal cancer. The drug is administered orally. It is a 6,7-dialkoxy quinazoline derivative, or salt derivative which possess anti-cancer activity. It acts by targeting the epidermal growth factor receptor (EGFR). It was also under development for advanced solid malignancies like non small cell lung cancer and HER-2 positive breast cancer.

Natco Pharma overview

Natco Pharma focuses on the discovery, development, manufacturing, and commercialization of pharmaceutical substances and finished dosage forms. The company offers finished dosages in capsule, injection and tablet forms. Its products are indicated to treat multiple sclerosis, influenza infection, multiple myeloma, leukemia, Crohn’s disease, hypertension, myelodysplastic syndrome, prostate cancer and others. Natco Pharma offers active pharmaceutical ingredients (APIs) in the domestic and international markets. It operates API and finished dosage facilities and a research center in India. The company operates in India, the US, Canada, and Europe. Natco Pharma is headquartered in Hyderabad, Telangana, India.

For a complete picture of NRC-2694’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.